• 제목/요약/키워드: hormone therapy

검색결과 412건 처리시간 0.022초

체외수정시술을 위한 성선자극호르몬 과배란유도에 Poor Response를 나타낸 환자에서 GnRH Analogue의 사용 (GnRH Analogue in Controlled Ovarian Hyperstimulation for Gonadotropin Poor Responder)

  • 김선행;이희경;구병삼
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제20권1호
    • /
    • pp.37-43
    • /
    • 1993
  • In 27 patients with the past history of poor response to the gonadotropin superovulation induction due to poor follicular growth or permature surge of endogenous luteinizing hormone, the effectiveness of pituitary supperssion with the gonadotropin releasing hormone agonist(GnRH-a) in in vitro fertilization(IVF) program was evaluated in 43 cycles using a combination regimen of D-Trp-6 LHRH(Decapeptyl, Ferring)and FSH/hMG from June, 1989 to August, 1990 at Korea University Hospital IVF Clinic. At midluteal phase of menstrual cycle, Decapeptyl-CR was administered by long-term protocol to minimize initial agonistic effect of endogenous gonadotropins. After the confirmation of pituitary suppression, about 2-3 weeks after GNRH-a administration, ovarian follicle growth was stimulated with FSH/hMG and followed by transvaginal ultrasonic measurement of follicle size and by monitoring of serm E2 and LH if necessary. When compared with the control group stimulated with gonadotropin regimen only, the cancellation rate and occurrence rate of premature LH surge during gonadotropin treatment were significantly lower in study group(11.6% and 2.4%, respectively). There is no significant differences in the mean number of aspirated oocytes, fertilization/cleavage rate, embryo transfer(ET) rate, and mean number of embryos transferred between the two groups. The pregnancy rate per treatment cycle, 16.3%, and per ET cycle, 23.3%, were significantly higher in the study group compared with those of control group. These data suggest that GnRH-a therapy is effective for previous poor responder In gonadotropin superovulation induction for IVF.

  • PDF

월경전증후군의 한약 치료 효과에 관한 무작위대조비교임상시험연구에 대한 고찰 (Review of Randomized Controlled Trials on the Therapeutic Effects of Herb Medicine for Premenstrual Syndrome)

  • 김수경;윤영진
    • 대한한방부인과학회지
    • /
    • 제33권4호
    • /
    • pp.36-55
    • /
    • 2020
  • Objectives: The present study is carried out to review the efficacy of Korean, Oriental medicine on premenstrual syndrome. Methods: We searched for 7 internet worldwide databases in order to find the studies with the keywords of 'premenstrual syndrome', 'premenstrual syndrome & Oriental medicine', 'premenstrual syndrome & traditional Chinese medicine' and 'premenstrual syndrome & herbal medicine' from 2009 to 2019. after selecting studies based on own criteria, total 8 studies are finally included. the studies were assessed with the Cochrane risk of bias criteria and reviewed systematically. Results: After intervention, cured patient rate in test groups in all of studies were significantly higher than rate in control group. there were significant decrease in headache, anorexia, dry mouth, breast mass, mastodynia, agitation, irascibility, edema, dizziness, fever, anhedonia, depression, inability to sleep, profuse dreaming with herbal medicinal intervention. 3 of those studies checked hormonal level. Estradiol (E2) and Progesteron (P) changed significantly in 2 of studies. Prolactin (PRL) in 1 study decreased significantly. FSH (Follicle stimulating hormone) and LH (Luteinizing hormone) had no significant decrease in 1 study. Conclusions: This review suggests that herbal medicine on premenstrual syndrome is effective without serious adverse effects. however, since unclear risk of bias, the result of this study should be considered carefully. further clinical trials should be carried out in order to academical clinical progress regarding treatment of premenstrual syndrome.

The Inhibitory Effects of Ahnjeonbaekho-tang on FRTL-5 Cell Proliferation and Thyroxine Synthesis

  • ;;;;안세영
    • 대한한방내과학회지
    • /
    • 제27권3호
    • /
    • pp.653-663
    • /
    • 2006
  • Objective : Graves' disease, the most common cause of hyperthyroidism, is an autoimmune disorder associated with autoantibodies to the TSH receptor. The clinical features of Graves' disease are goiter and hypermetabolic symptoms induced by excessive hormones. Antithyroid drug therapy is the first-line treatment for Graves' disease in Korea, Japan and European countries. Yet in spite of a long period and high-dose of treatment, it is hard to achieve remission because of adverse effects, frequent recurrence and resistance to antithyroid drugs. Recently, it has been reported that the abnormal thyroid hormone and clinical symptoms of Graves' disease were reduced by Ahnjeonbaekho-tang (AJBHT). Methods : To investigate the effectiveness and action mechanism of AJBHT, we studied the influence of AJBHT on FRTL-5 thyroid cell proliferation, DNA synthesis and expression of T4, TSH, cAMP, Tg and TPO mRNA. Results : AJBHT significantly inhibited the FRTL-5 cell proliferation, DNA synthesis, T4 synthesis, cAMP production and the expression of Tg mRNA in comparison with control and MMI. Conclusions : These results suggest that AJBHT may inhibit the cell proliferation and DNA synthesis by regulating the cAMP, and suppress the T4 synthesis by modulating Tg mRNA expression and cAMP synthesis, and that it may be useful agent for treating the goiter and hormone abnormality of Graves' disease.

  • PDF

Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment

  • Phung, Hung Manh;Jang, Dongyeop;Trinh, Tuy An;Lee, Donghun;Nguyen, Quynh Nhu;Kim, Chang-Eop;Kang, Ki Sung
    • Journal of Ginseng Research
    • /
    • 제46권4호
    • /
    • pp.609-619
    • /
    • 2022
  • Obesity is a primary factor provoking various chronic disorders, including cardiovascular disease, diabetes, and cancer, and causes the death of 2.8 million individuals each year. Diet, physical activity, medications, and surgery are the main therapies for overweightness and obesity. During weight loss therapy, a decrease in energy stores activates appetite signaling pathways under the regulation of neuropeptides, including anorexigenic [corticotropin-releasing hormone, proopiomelanocortin (POMC), cholecystokinin (CCK), and cocaine- and amphetamine-regulated transcript] and orexigenic [agoutirelated protein (AgRP), neuropeptide Y (NPY), and melanin-concentrating hormone] neuropeptides, which increase food intake and lead to failure in attaining weight loss goals. Ginseng and ginsenosides reverse these signaling pathways by suppressing orexigenic neuropeptides (NPY and AgRP) and provoking anorexigenic neuropeptides (CCK and POMC), which prevent the increase in food intake. Moreover, the results of network pharmacology analysis have revealed that constituents of ginseng radix, including campesterol, beta-elemene, ginsenoside Rb1, biotin, and pantothenic acid, are highly correlated with neuropeptide genes that regulate energy balance and food intake, including ADIPOQ, NAMPT, UBL5, NUCB2, LEP, CCK, GAST, IGF1, RLN1, PENK, PDYN, and POMC. Based on previous studies and network pharmacology analysis data, ginseng and its compounds may be a potent source for obesity treatment by regulating neuropeptides associated with appetite.

Parathyroid Hormone-Related Protein Promotes the Proliferation of Patient-Derived Glioblastoma Stem Cells via Activating cAMP/PKA Signaling Pathway

  • Zhenyu Guo;Tingqin Huang;Yingfei Liu;Chongxiao Liu
    • International Journal of Stem Cells
    • /
    • 제16권3호
    • /
    • pp.315-325
    • /
    • 2023
  • Background and Objectives: Glioblastoma (GBM) is an aggressive primary brain tumor characterized by its heterogeneity and high recurrence and lethality rates. Glioblastoma stem cells (GSCs) play a crucial role in therapy resistance and tumor recurrence. Therefore, targeting GSCs is a key objective in developing effective treatments for GBM. The role of Parathyroid hormone-related peptide (PTHrP) in GBM and its impact on GSCs remains unclear. This study aimed to investigate the effect of PTHrP on GSCs and its potential as a therapeutic target for GBM. Methods and Results: Using the Cancer Genome Atlas (TCGA) database, we found higher expression of PTHrP in GBM, which correlated inversely with survival. GSCs were established from three human GBM samples obtained after surgical resection. Exposure to recombinant human PTHrP protein (rPTHrP) at different concentrations significantly enhanced GSCs viability. Knockdown of PTHrP using target-specific siRNA (siPTHrP) inhibited tumorsphere formation and reduced the number of BrdU-positive cells. In an orthotopic xenograft mouse model, suppression of PTHrP expression led to significant inhibition of tumor growth. The addition of rPTHrP in the growth medium counteracted the antiproliferative effect of siPTHrP. Further investigation revealed that PTHrP increased cAMP concentration and activated the PKA signaling pathway. Treatment with forskolin, an adenylyl cyclase activator, nullified the antiproliferative effect of siPTHrP. Conclusions: Our findings demonstrate that PTHrP promotes the proliferation of patient-derived GSCs by activating the cAMP/PKA signaling pathway. These results uncover a novel role for PTHrP and suggest its potential as a therapeutic target for GBM treatment.

폐경후 호르몬대체요법에 대한 인터넷 웹싸이트 자료 내용 및 학술 연구 경향 분석과 국내 한방병원 내원환자에 관한 연구 (A Study about the News Searched on Web-site Related to HRT and Analysis of Perimenopausal and Postmenopausal Patient Who Visited Dept, of Ob&Gy Korean Medicine Hospital)

  • 김동일
    • 대한한방부인과학회지
    • /
    • 제19권1호
    • /
    • pp.219-235
    • /
    • 2006
  • Purpose : To investigate the medical information related to HRT online and the medical treatment of perimenopausal and postmenopausal women in the Dept. of Ob&Gy Korean Medicine Hospital, after the discontinuance of the WHI trial in U.S, July 2002. Methods : With the key-words "HRT", "Hormone Replacement therapy", "호르몬 대체요법(HRT)", 갱년기 증후군(perimenopausal syndrome)", “폐경기후증후군(postmenopausal syndrome)", I searched for the information from July 2002 to 2005 on DAUM, the representative portal site in Korea, and I've got a grasp of the tendency of the informational propagation on HRT. Moreover, I investigated chief complaints and tendency of give up HRT of the perimenopausal and postmenopausal women(aged between 47 and 60) who visited Dept. of Ob&Gy Korean Medicine Hospital for 2 years and 6 months since July 2002. Results : 1) Searching for the news on DAUM, I found; 2 articles on the methods of HRT: 4 on the positive effects of HRT: 4 on the general items including the positive effects of HRT: 19 on the side effects of HRT: 1 on the insignificant effect of HRT :4 on the apprehensions about HRT: 3 on the strengthening of the criteria on medical fees review: 3 on the discontinuance of HRT: 8 on the alternative materials and medicines to HRT: 4 on the guidance for the phyto-estrogen. 2) I analyzed chief complaints of 120 women. The majority of chief complaints were vasomotor symptoms like hot flush and sweating. There were only 4 patients who wanted to give up HRT. Conclusion : The side effects of HRT were objectively dealt with online but there was not enough effective and continuous guidance. In the case that a woman not on HRT wishes to overcome perimenopausal period through KM therapy, this information may have affected her decision. However, not many women who were already on HRT terminated the therapy for fear of side effects and switched to KM therapy. Promotion of KM therapy in improving health during perimenopausal and postmenopausal period is desperately needed.

  • PDF

프래더 윌리 증후군의 유전학적 발병 기전에 따른 표현형 및 성장 호르몬 치료 효과에 관한 연구 (Phenotype-genotype correlations and the efficacy of growth hormone treatment in Korean children with Prader-Willi syndrome)

  • 배근욱;고정민;유한욱
    • Clinical and Experimental Pediatrics
    • /
    • 제51권3호
    • /
    • pp.315-322
    • /
    • 2008
  • 목 적 : PWS의 두 가지 대표적 유전형인 미세결실형과 mUPD (15)형에서, 유전형에 따른 표현형의 차이와 성장 호르몬 투여 효과의 차이를 비교해 보고자 하였다. 방 법 : 1990년 1월부터 2007년 1월까지 서울아산병원에서 15번 염색체의 미세 결실에 대한 FISH 검사 및 메틸화-특이 PCR 검사를 통해 PWS로 확진된 53명의 환자를 대상으로 하였다. 출생시 부모의 연령, 출생 체중, PWS의 주요 표현형인 신생아 시기의 저긴장증, 수유 문제, 남아의 경우 잠복 고환, 발달 지연 및 정신 지체, 저신장, 저색소증, 사시, 척추측만증 등의 유무, 성장 호르몬 치료 전과 치료 후의 신장, 체중, 체질량 지수의 변화를 조사하였고 미세결실형 군과 mUPD(15)형 군으로 나누어 유전형에 따른 차이를 분석하였다. 결 과 : 유전학적 검사상 53명의 대상 환아 모두 미세결실형 또는 mUPD(15)형으로 진단되었으며, 미세결실형은 39명, mUPD (15)형은 14명이었다. 평균 진단 연령은 $4.51{\pm}5.19$세였다. 출생 당시 부모의 연령은 mUPD(15)형 군에서 유의하게 높았으며(P=0.0001), 저색소증(P=0.0001)과 신생아기의 수유 부전(P=0.049)은 미세결실형에서 유의하게 많았으나, 그 외의 조사된 표현형에서는 두 군 간에 통계적으로 의미 있는 차이는 없었다. 성장 호르몬은 20명의 환아[미세결실형 14명, mUPD(15)형 6명]에게 평균 $27.9{\pm}11.9$개월 동안 투여되었다. 두 유전형 간에 성장 호르몬 치료 전 및 치료 후의 신장 SDS, 체중 SDS, 체질량지수, IGF-1, IGFBP3, 신장 증가 속도, 체중 증가 속도의 값에는 의미 있는 차이가 없었다. 결 론 : PWS의 주요한 두 유전형의 비교에서, 부모의 연령은 mUPD(15)형에서 의미 있게 높았으며 신생아기 수유 부전과 저색소증은 결실형에서 의미 있게 많았다. 성장 호르몬의 치료 효과에서는 두 유전형 간에 의미 있는 반응의 차이는 없었다. 향후 두 유전자형과 다른 표현형들(예를 들면 행동, 발달, 지능 등) 과의 연관성에 관한 전향적 연구가 더 필요할 것으로 생각된다.

일 지역 중년여성의 폐경증상과 폐경관리와의 관계에 대한 연구 (An Analysis of the Relationship between Climacteric Symptoms and Management of Menopause in Middle-aged Women)

  • 송애리
    • 한국간호교육학회지
    • /
    • 제7권2호
    • /
    • pp.308-322
    • /
    • 2001
  • The purpose of this study was to investigate the relationship between climacteric symptoms and management of menopause of middle -aged women. The subjects of this study were 261 women(40 to 60 years old). Data were collected from Jun. 1 to Jul. 15, 2001 by a structured questionnaire. The instruments employed were : 1) The Climacteric Symptoms Scale developed by Aeri Song and Eun soon Chung(1998). 2) The Management of Menopause Scale developed by Aeri Song(1997). The data were analyzed by the SPSS p.c. program using t-test, ANOVA and Pearson correlation coefficient. The results of the study were as follows : 1. Mean score of climacteric symptoms was $2.18{\pm}0.39$(Maximum 4, Minimum 1). The mean scores among the categories of climacteric symptoms, in descending order, were : a) physical and physiological reactions ($2.62{\pm}0.53$), b) social and family relationships ($2.23{\pm}0.50$), c) psychiatric and psychological reactions ($2.08{\pm}0.49$), d) relationship with sexual partner($1.73{\pm}0.54$), e) genitourinary reactions ($1.72{\pm}0.55$). 2. Mean score of management of menopause was $1.79{\pm}0.45$ (Maximum 4, Minimum 1). The mean scores among the categories of management of menopause, in descending order, were : a) dietary management($2.57{\pm}0.52$), b) self control ($2.24{\pm}0.57$), c) management of exercise and physical activity($2.14{\pm}0.75$), d) management of sex life($1.71{\pm}0.47$), e) management of professional health maintenance($1.61{\pm}0.59$). 3. There were statistically significant differences in the score of middle-aged women's self reported climacteric symptoms according to : a) occupation (t=-2.79, p<0.001) b) marriage state (t=-2.29, p<0.05) c) age of menarche (F=4.66, p<0.001) d) method of Sanhujori (post natal care & treatment) (F=4.22, p<0.001) e) hormone replacement therapy (t=-3.09, p<0.05). From the above statistics, several significant findings were noted : a) There were more climacteric symptoms from those who were unemployed, those who had no partner or were divorced and those who started a menarche earlier. b) There were less climacteric symptoms reported from those on hormone replacement therapy and those who followed their parents or parents-in-law advice regarding Sanhujori (postnatal care) 4. There were statistically significant differences in the score of middle-aged women's self reported management of menopause according to : The educational background (F=7.63, p<0.001), religion (F=3.74, p<0.001), income (F=3.65, p<0.001), number of parity (F=4.87, p<0.001), method of Sanhujori(postnatal care) (F=5.73, p<0.001), period of Sanhujori (postnatal care) (F=2.81, p<0.05), hormone replacement therapy (t=3.81, p<0.001). Women with higher educational background, strong religion, higher income, large number of parity, managed their post natal care well, were on HRT, managed their menopause significantly better than the others who took part in the survey. 5. It will be noted from the above that women's degree of climacteric symptoms showed a negative correlation to the management of menopause(r=-0.2146, p<0.001). The findings shown above suggest the need to develop a variable management of menopause, in order to improve climacteric symptoms of middle-aged women. It is hoped that the above findings will stimulate more detailed research into this matter, and thereby enable guidance to be given to women going through the menopause to cope with it in a less stressful way.

  • PDF

골 대사 및 phytochemicals의 estrogen 효과 (Bone Metabolism and Estrogenic Effect of Phytochemicals)

  • 김보경;김미향
    • 생명과학회지
    • /
    • 제28권7호
    • /
    • pp.874-883
    • /
    • 2018
  • 전 세계적인 인구 고령화 현상으로 인하여 골다공증은 주요한 질병으로 대두되고 있다. 골다공증은 뼈의 질량과 강도가 감소하여 골절의 위험이 증가하는 질환으로 조골세포의 골 형성 및 파골세포의 골 흡수의 불균형으로 인해 발생하는 질환이다. 조골세포에 의한 골 형성은 BMP, RUNX2, $Wnt/{\beta}-catenin$ 경로 등을 통하여 활성화 되며, 파골세포에 의한 골 흡수는 RANKL과 RANK의 결합에 의해서 시작된다. 폐경기 여성은 호르몬 불균형에 의해 여러 질병의 위험에 처해 있으며, 폐경기 여성의 약 30%에서 관찰되는 골다공증은 폐경기 여성에게서 발생되는 가장 흔한 대사성 질환이기도 하다. Estrogen이 부족할 때 파골세포의 골 흡수가 촉진되므로, 특히 폐경 여성에서 골다공증의 발생위험이 증가하게 된다. 호르몬대체요법은 폐경기 증후군의 증상을 경감시키거나 치료하기 위해 널리 사용되어 왔으나, 호르몬 치료를 장기간 실시할 경우 유방암, 난소암, 자궁암 등의 부작용 위험성이 매우 높은 것으로 알려져 있다. 따라서 최근 들어 여러 부작용을 보완하기 위해 폐경기 증후군 증상에 대처할 수 있는 estrogen과 유사한 활성을 지닌 식물성 estrogen인 phytoestrogen에 대한 연구가 활발히 진행되고 있다. 따라서, 본 총설에서는 조골세포 및 파골세포의 분화 기전에 대한 선행연구를 알아보고 골 대사에서의 estrogen의 역할 및 phytoestrogen과 관련한 연구들에 대해서도 살펴보았다.

Misuse of testosterone replacement therapy in men in infertile couples and its influence on infertility treatment

  • Song, Seung-Hun;Sung, Suye;Her, Young Sun;Oh, Mihee;Shin, Dong Hyuk;Lee, Jinil;Baek, Jeongwon;Lee, Woo Sik;Kim, Dong Suk
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제46권4호
    • /
    • pp.173-177
    • /
    • 2019
  • Objective: We investigated the clinical characteristics of men with testosterone replacement therapy (TRT)-induced hypogonadism and its effect on assisted reproductive technology (ART) in infertile couples. Methods: This study examined the records of 20 consecutive male patients diagnosed with azoospermia or severe oligozoospermia (< 5 × 106/mL) who visited a single infertility center from January 2008 to July 2018. All patients were treated at a primary clinic for erectile dysfunction or androgen deficiency symptoms combined with low serum testosterone. All men received a phosphodiesterase 5 inhibitor and TRT with testosterone undecanoate (Nebido®) or testosterone enanthate (Jenasteron®). Patients older than 50 years or with a chronic medical disease such as diabetes were excluded. Results: The mean age of patients was 37 years and the mean duration of infertility was 16.3 ± 11.6 months. At the initial presentation, eight patients had azoospermia, nine had cryptozoospermia, and three had severe oligozoospermia. Serum follicle-stimulating hormone levels were below 1.0 mIU/mL in most patients. Three ongoing ART programs with female factor infertility were cancelled due to male spermatogenic dysfunction; two of these men had normal semen parameters in the previous cycle. After withholding TRT, serum hormone levels and sperm concentrations returned to normal range after a median duration of 8 months. Conclusion: TRT with high-dose testosterone can cause spermatogenic dysfunction due to suppression of the hypothalamic-pituitary-testicular axis, with adverse effects on infertility treatment programs. TRT is therefore contraindicated for infertile couples attempting to conceive, and the patient's desire for fertility must be considered before initiation of TRT in a hypogonadal man.